HIV-1 Infection - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：292頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
HIV-1 Infection - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘HIV-1 Infection - Pipeline Review, H1 2014’, provides an overview of the HIV-1 Infection’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for HIV-1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV-1 Infection and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of HIV-1 Infection
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for HIV-1 Infection and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the HIV-1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the HIV-1 Infection pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘HIV-1 Infection - Pipeline Review, H1 2014’, provides an overview of the HIV-1 Infection’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for HIV-1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV-1 Infection and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of HIV-1 Infection
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for HIV-1 Infection and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the HIV-1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the HIV-1 Infection pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
HIV-1 Infection Overview 10
Therapeutics Development 11
Pipeline Products for HIV-1 Infection - Overview 11
Pipeline Products for HIV-1 Infection - Comparative Analysis 12
HIV-1 Infection - Therapeutics under Development by Companies 13
HIV-1 Infection - Therapeutics under Investigation by Universities/Institutes 17
HIV-1 Infection - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
HIV-1 Infection - Products under Development by Companies 24
HIV-1 Infection - Products under Investigation by Universities/Institutes 28
HIV-1 Infection - Companies Involved in Therapeutics Development 32
Bristol-Myers Squibb Company 32
Johnson & Johnson 33
Boehringer Ingelheim GmbH 34
GlaxoSmithKline plc 35
Inovio Pharmaceuticals, Inc. 36
Gilead Sciences, Inc. 37
Merck & Co., Inc. 38
United Biomedical, Inc. 39
Kaketsuken K.K. 40
Aphios Corporation 41
Pfizer Inc. 42
Koronis Pharma, Inc. 43
Crucell N.V. 44
GeoVax Labs, Inc. 45
Enzo Biochem, Inc. 46
ConjuChem Biotechnologies Inc. 47
Critical Outcome Technologies Inc. 48
Takara Bio Inc. 49
Bionor Pharma ASA 50
Quantum Pharmaceuticals 51
Italfarmaco S.p.A. 52
Vironova AB 53
ViroStatics, srl 54
Argos Therapeutics, Inc. 55
Myrexis, Inc. 56
GeneCure LLC 57
Tobira Therapeutics, Inc. 58
Pharis Biotec GmbH 59
Medestea Research & Production S.p.A. 60
ViiV Healthcare Limited 61
RFS Pharma, LLC 62
Vichem Chemie Research Ltd. 63
AltraVax Inc. 64
TaiMed Biologics Inc. 65
InnaVirVax SA 66
Valens Therapeutics, Inc. 67
Susavion Biosciences, Inc. 68
AbbVie Inc. 69
HIV-1 Infection - Therapeutics Assessment 70
Assessment by Monotherapy Products 70
Assessment by Combination Products 71
Assessment by Target 72
Assessment by Mechanism of Action 76
Assessment by Route of Administration 80
Assessment by Molecule Type 82
Drug Profiles 85
(dolutegravir + abacavir sulphate + lamivudine) - Drug Profile 85
(cobicistat + darunavir) - Drug Profile 87
dapivirine - Drug Profile 88
(elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide) - Drug Profile 90
ALVAC-HIV vCP1521 + AIDSVAX B/B - Drug Profile 92
(atazanavir sulfate + cobicistat) - Drug Profile 94
(cobicistat + darunavir) - Drug Profile 96
ABT-450/r + ABT-267 + dasabuvir - Drug Profile 97
pGA2/JS7 DNA Vaccine + Recombinant Modified Vaccinia Ankara/HIV62B Vaccine - Drug Profile 100
censavudine - Drug Profile 102
amdoxovir - Drug Profile 103
cenicriviroc - Drug Profile 105
AGS-004 - Drug Profile 107
(didanosine + hydroxyurea) - Drug Profile 109
Vacc-4x - Drug Profile 111
BMS-663068 - Drug Profile 114
TMC-310911 - Drug Profile 116
KP-1461 - Drug Profile 117
VRC-HIVDNA016-00-VP Vaccine - Drug Profile 119
HIV-1 Tat Vaccine - Drug Profile 121
UB-421 - Drug Profile 122
GSK-732462 - Drug Profile 123
doravirine - Drug Profile 124
VAC-3S - Drug Profile 125
(darunavir + cobicistat + emtricitabine + tenofovir alafenamide) - Drug Profile 127
BMS-955176 - Drug Profile 129
HGTV-43 - Drug Profile 130
Dendritic Cell Vaccine - Drug Profile 131
VRC-HIVADV014-00-VP Vaccine - Drug Profile 132
TUTI-16 - Drug Profile 134
VRC-HIVDNA016-00-VP Vaccine - Drug Profile 135
Tat Oyi Vaccine - Drug Profile 137
Ad26.ENVA.01 Vaccine - Drug Profile 139
rilpivirine - Drug Profile 141
BIIR/ANRS-HIVax-001 - Drug Profile 143
PENNVAX-B DNA Vaccine - Drug Profile 144
Ad5.ENVA.48 HIV-1 vaccine - Drug Profile 146
MVA-B Vaccine - Drug Profile 147
DNA Vaccine + Recombinant Adenoviral Subtype 5 + Recombinant Adenoviral Subtype 35 - Drug Profile 148
MVA.HIVconsv Vaccine - Drug Profile 150
rAd5 Env A Vaccine - Drug Profile 152
KD-247 - Drug Profile 153
aldesleukin + CD-4 Zeta Gene-Modified T Cells - Drug Profile 154
Plasmid DNA-MVA Prime Boost HIV-1 Vaccine - Drug Profile 155
APH-0812 - Drug Profile 156
Replication Defective HIV-1 Vaccine - Drug Profile 157
Clade B HIV Vaccine - Drug Profile 159
MazF-Based HIV-1 Gene Therapy - Drug Profile 161
AFO-18-CAF01 Vaccine - Drug Profile 163
TMB-657 - Drug Profile 164
VRC-01 - Drug Profile 165
DNA-HIV-PT123 + NYVAC-HIV-PT1 + NYVAC-HIV-PT4 - Drug Profile 167
HIV Vaccine - Drug Profile 169
Teravac HIV-1 Vaccine - Drug Profile 170
rAd5HVR48 HIV-1 Vaccine - Drug Profile 171
Retroviral Transduced T-Cell Therapy For HIV - Drug Profile 172
Anti-HIV Monoclonal Antibody - Drug Profile 173
L-644 - Drug Profile 174
HIV-1 Integrase Inhibitors - Drug Profile 175
DAC-HIV - Drug Profile 177
Leukothera - Drug Profile 178
Small Molecules to Inhibit CDK9 for HIV-1 Infection - Drug Profile 179
AT-96 - Drug Profile 180
GS-8374 - Drug Profile 181
HIV-1 Vaccine - Drug Profile 182
DS-003 - Drug Profile 183
M48-U1 - Drug Profile 184
Azuvirins - Drug Profile 186
Mutated tRNAs - Drug Profile 187
HIV Vaccine - Drug Profile 188
Cell Therapy for HIV-1 Infection - Drug Profile 189
Peptides Targeting TAR for HIV-1 Infection - Drug Profile 190
HIV-1 Integrase Inhibitor for Viral Infections - Drug Profile 192
HIV-1 Vaccine - Drug Profile 193
F2 - Drug Profile 194
SVC-2 - Drug Profile 195
SV6-B - Drug Profile 196
SV6-C - Drug Profile 197
SVH1-C - Drug Profile 198
Nuclear Export Inhibitors - Drug Profile 199
BMS-585248 - Drug Profile 200
VRC-03 Vaccine - Drug Profile 201
HIV-1 Mosaic Vaccine - Drug Profile 202
Tropolone Derivatives - Drug Profile 203
SIV Vaccine - Drug Profile 204
Cyclic V3 Peptide Vaccine - Drug Profile 205
Drug Targeting HIV-1 Reverse Transcriptase - Drug Profile 206
INS Peptide - Drug Profile 207
INRS Peptide - Drug Profile 208
Compounds Mimicking CD-4 Protein - Drug Profile 209
Maturation Inhibitor for HIV-1 - Drug Profile 210
CCL-14 - Drug Profile 211
givinostat - Drug Profile 212
HIV-1 Program - Drug Profile 214
aminoquinuride - Drug Profile 215
Drug For HIV-1 Infection - Drug Profile 216
PF-46396 - Drug Profile 217
PAV-8802 Series - Drug Profile 218
Small Molecules to Inhibit p25 and gp120 for HIV-1 Infection - Drug Profile 219
RC-100b - Drug Profile 220
Polyvalent HIV-1 Glycoprotein DNA Vaccines - Drug Profile 222
Drugs to Inhibit HIV-1 Protease for HIV-1 Infection - Drug Profile 223
RN-18 - Drug Profile 224
Ank(GAG)1D4 - Drug Profile 225
5-HN - Drug Profile 226
Drug Targeting Glycoprotein 41 - Drug Profile 227
Small Molecules to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection - Drug Profile 228
SVH1-D - Drug Profile 229
Compound-30 - Drug Profile 230
Compound-7 - Drug Profile 231
Drug For HIV-1 - Drug Profile 232
Small Molecule for HIV-1 Infection - Drug Profile 233
Nelfinavir Analogue - Drug Profile 234
Drugs Targeting HIV-1 Reverse Transcriptase for HIV-1 Infection - Drug Profile 235
Polypeptide For HIV-1 - Drug Profile 236
Drug For HIV-1 Infection - Drug Profile 237
GRL-0519 - Drug Profile 238
VRC-02 Vaccine - Drug Profile 239
Compound 11-b - Drug Profile 240
Drug to Inhibit Vif Protein for HIV-1 Infection - Drug Profile 241
Compound X - Drug Profile 242
Recombinant Peptides for HIV-1 Infection and STDs - Drug Profile 243
Drugs to Inhibit Reverse Transcriptase for Viral Infections - Drug Profile 244
AH-0109 - Drug Profile 245
HIV-1 Infection - Recent Pipeline Updates 246
HIV-1 Infection - Dormant Projects 267
HIV-1 Infection - Discontinued Products 274
HIV-1 Infection - Product Development Milestones 275
Featured News & Press Releases 275
Appendix 282
Methodology 282
Coverage 282
Secondary Research 282
Primary Research 282
Expert Panel Validation 282
Contact Us 283
Disclaimer 283
List of Tables
Number of Products under Development for HIV-1 Infection, H1 2014 20
Number of Products under Development for HIV-1 Infection - Comparative Analysis, H1 2014 21
Number of Products under Development by Companies, H1 2014 23
Number of Products under Development by Companies, H1 2014 (Contd..1) 24
Number of Products under Development by Companies, H1 2014 (Contd..2) 25
Number of Products under Investigation by Universities/Institutes, H1 2014 27
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 28
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 29
Comparative Analysis by Late Stage Development, H1 2014 30
Comparative Analysis by Clinical Stage Development, H1 2014 31
Comparative Analysis by Early Stage Development, H1 2014 32
Products under Development by Companies, H1 2014 33
Products under Development by Companies, H1 2014 (Contd..1) 34
Products under Development by Companies, H1 2014 (Contd..2) 35
Products under Development by Companies, H1 2014 (Contd..3) 36
Products under Investigation by Universities/Institutes, H1 2014 37
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 38
Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 39
Products under Investigation by Universities/Institutes, H1 2014 (Contd..3) 40
HIV-1 Infection - Pipeline by Bristol-Myers Squibb Company, H1 2014 41
HIV-1 Infection - Pipeline by Johnson & Johnson, H1 2014 42
HIV-1 Infection - Pipeline by Boehringer Ingelheim GmbH, H1 2014 43
HIV-1 Infection - Pipeline by GlaxoSmithKline plc, H1 2014 44
HIV-1 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2014 45
HIV-1 Infection - Pipeline by Gilead Sciences, Inc., H1 2014 46
HIV-1 Infection - Pipeline by Merck & Co., Inc., H1 2014 47
HIV-1 Infection - Pipeline by United Biomedical, Inc., H1 2014 48
HIV-1 Infection - Pipeline by Kaketsuken K.K., H1 2014 49
HIV-1 Infection - Pipeline by Aphios Corporation, H1 2014 50
HIV-1 Infection - Pipeline by Pfizer Inc., H1 2014 51
HIV-1 Infection - Pipeline by Koronis Pharma, Inc., H1 2014 52
HIV-1 Infection - Pipeline by Crucell N.V., H1 2014 53
HIV-1 Infection - Pipeline by GeoVax Labs, Inc., H1 2014 54
HIV-1 Infection - Pipeline by ConjuChem Biotechnologies Inc., H1 2014 56
HIV-1 Infection - Pipeline by Critical Outcome Technologies Inc., H1 2014 57
HIV-1 Infection - Pipeline by Takara Bio Inc., H1 2014 58
HIV-1 Infection - Pipeline by Bionor Pharma ASA, H1 2014 59
HIV-1 Infection - Pipeline by Quantum Pharmaceuticals, H1 2014 60
HIV-1 Infection - Pipeline by Italfarmaco S.p.A., H1 2014 61
HIV-1 Infection - Pipeline by Vironova AB, H1 2014 62
HIV-1 Infection - Pipeline by ViroStatics, srl, H1 2014 63
HIV-1 Infection - Pipeline by Argos Therapeutics, Inc., H1 2014 64
HIV-1 Infection - Pipeline by Myrexis, Inc., H1 2014 65
HIV-1 Infection - Pipeline by GeneCure LLC, H1 2014 66
HIV-1 Infection - Pipeline by Tobira Therapeutics, Inc., H1 2014 67
HIV-1 Infection - Pipeline by Pharis Biotec GmbH, H1 2014 68
HIV-1 Infection - Pipeline by Medestea Research & Production S.p.A., H1 2014 69
HIV-1 Infection - Pipeline by ViiV Healthcare Limited, H1 2014 70
HIV-1 Infection - Pipeline by RFS Pharma, LLC, H1 2014 71
HIV-1 Infection - Pipeline by Vichem Chemie Research Ltd., H1 2014 72
HIV-1 Infection - Pipeline by AltraVax Inc., H1 2014 73
HIV-1 Infection - Pipeline by TaiMed Biologics Inc., H1 2014 74
HIV-1 Infection - Pipeline by InnaVirVax SA, H1 2014 75
HIV-1 Infection - Pipeline by Valens Therapeutics, Inc., H1 2014 76
HIV-1 Infection - Pipeline by Susavion Biosciences, Inc., H1 2014 77
HIV-1 Infection - Pipeline by AbbVie Inc., H1 2014 78
Assessment by Monotherapy Products, H1 2014 79
Assessment by Combination Products, H1 2014 80
Number of Products by Stage and Target, H1 2014 83
Number of Products by Stage and Mechanism of Action, H1 2014 87
Number of Products by Stage and Route of Administration, H1 2014 90
Number of Products by Stage and Molecule Type, H1 2014 93
HIV-1 Infection Therapeutics - Recent Pipeline Updates, H1 2014 255
HIV-1 Infection - Dormant Projects, H1 2014 276
HIV-1 Infection - Dormant Projects (Contd..1), H1 2014 277
HIV-1 Infection - Dormant Projects (Contd..2), H1 2014 278
HIV-1 Infection - Dormant Projects (Contd..3), H1 2014 279
HIV-1 Infection - Dormant Projects (Contd..4), H1 2014 280
HIV-1 Infection - Dormant Projects (Contd..5), H1 2014 281
HIV-1 Infection - Dormant Projects (Contd..6), H1 2014 282
HIV-1 Infection - Discontinued Products, H1 2014 283
List of Figures
Number of Products under Development for HIV-1 Infection, H1 2014 20
Number of Products under Development for HIV-1 Infection - Comparative Analysis, H1 2014 21
Number of Products under Development by Companies, H1 2014 22
Number of Products under Investigation by Universities/Institutes, H1 2014 26
Comparative Analysis by Late Stage Development, H1 2014 30
Comparative Analysis by Clinical Stage Development, H1 2014 31
Comparative Analysis by Early Stage Products, H1 2014 32
Assessment by Monotherapy Products, H1 2014 79
Assessment by Combination Products, H1 2014 80
Number of Products by Top 10 Target, H1 2014 81
Number of Products by Stage and Top 10 Target, H1 2014 82
Number of Products by Top 10 Mechanism of Action, H1 2014 85
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 86
Number of Products by Top 10 Route of Administration, H1 2014 89
Number of Products by Stage and Top 10 Route of Administration, H1 2014 90
Number of Products by Top 10 Molecule Type, H1 2014 91
Number of Products by Stage and Top 10 Molecule Type, H1 2014 92
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
HIV-1 Infection Overview 10
Therapeutics Development 11
Pipeline Products for HIV-1 Infection - Overview 11
Pipeline Products for HIV-1 Infection - Comparative Analysis 12
HIV-1 Infection - Therapeutics under Development by Companies 13
HIV-1 Infection - Therapeutics under Investigation by Universities/Institutes 17
HIV-1 Infection - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
HIV-1 Infection - Products under Development by Companies 24
HIV-1 Infection - Products under Investigation by Universities/Institutes 28
HIV-1 Infection - Companies Involved in Therapeutics Development 32
Bristol-Myers Squibb Company 32
Johnson & Johnson 33
Boehringer Ingelheim GmbH 34
GlaxoSmithKline plc 35
Inovio Pharmaceuticals, Inc. 36
Gilead Sciences, Inc. 37
Merck & Co., Inc. 38
United Biomedical, Inc. 39
Kaketsuken K.K. 40
Aphios Corporation 41
Pfizer Inc. 42
Koronis Pharma, Inc. 43
Crucell N.V. 44
GeoVax Labs, Inc. 45
Enzo Biochem, Inc. 46
ConjuChem Biotechnologies Inc. 47
Critical Outcome Technologies Inc. 48
Takara Bio Inc. 49
Bionor Pharma ASA 50
Quantum Pharmaceuticals 51
Italfarmaco S.p.A. 52
Vironova AB 53
ViroStatics, srl 54
Argos Therapeutics, Inc. 55
Myrexis, Inc. 56
GeneCure LLC 57
Tobira Therapeutics, Inc. 58
Pharis Biotec GmbH 59
Medestea Research & Production S.p.A. 60
ViiV Healthcare Limited 61
RFS Pharma, LLC 62
Vichem Chemie Research Ltd. 63
AltraVax Inc. 64
TaiMed Biologics Inc. 65
InnaVirVax SA 66
Valens Therapeutics, Inc. 67
Susavion Biosciences, Inc. 68
AbbVie Inc. 69
HIV-1 Infection - Therapeutics Assessment 70
Assessment by Monotherapy Products 70
Assessment by Combination Products 71
Assessment by Target 72
Assessment by Mechanism of Action 76
Assessment by Route of Administration 80
Assessment by Molecule Type 82
Drug Profiles 85
(dolutegravir + abacavir sulphate + lamivudine) - Drug Profile 85
(cobicistat + darunavir) - Drug Profile 87
dapivirine - Drug Profile 88
(elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide) - Drug Profile 90
ALVAC-HIV vCP1521 + AIDSVAX B/B - Drug Profile 92
(atazanavir sulfate + cobicistat) - Drug Profile 94
(cobicistat + darunavir) - Drug Profile 96
ABT-450/r + ABT-267 + dasabuvir - Drug Profile 97
pGA2/JS7 DNA Vaccine + Recombinant Modified Vaccinia Ankara/HIV62B Vaccine - Drug Profile 100
censavudine - Drug Profile 102
amdoxovir - Drug Profile 103
cenicriviroc - Drug Profile 105
AGS-004 - Drug Profile 107
(didanosine + hydroxyurea) - Drug Profile 109
Vacc-4x - Drug Profile 111
BMS-663068 - Drug Profile 114
TMC-310911 - Drug Profile 116
KP-1461 - Drug Profile 117
VRC-HIVDNA016-00-VP Vaccine - Drug Profile 119
HIV-1 Tat Vaccine - Drug Profile 121
UB-421 - Drug Profile 122
GSK-732462 - Drug Profile 123
doravirine - Drug Profile 124
VAC-3S - Drug Profile 125
(darunavir + cobicistat + emtricitabine + tenofovir alafenamide) - Drug Profile 127
BMS-955176 - Drug Profile 129
HGTV-43 - Drug Profile 130
Dendritic Cell Vaccine - Drug Profile 131
VRC-HIVADV014-00-VP Vaccine - Drug Profile 132
TUTI-16 - Drug Profile 134
VRC-HIVDNA016-00-VP Vaccine - Drug Profile 135
Tat Oyi Vaccine - Drug Profile 137
Ad26.ENVA.01 Vaccine - Drug Profile 139
rilpivirine - Drug Profile 141
BIIR/ANRS-HIVax-001 - Drug Profile 143
PENNVAX-B DNA Vaccine - Drug Profile 144
Ad5.ENVA.48 HIV-1 vaccine - Drug Profile 146
MVA-B Vaccine - Drug Profile 147
DNA Vaccine + Recombinant Adenoviral Subtype 5 + Recombinant Adenoviral Subtype 35 - Drug Profile 148
MVA.HIVconsv Vaccine - Drug Profile 150
rAd5 Env A Vaccine - Drug Profile 152
KD-247 - Drug Profile 153
aldesleukin + CD-4 Zeta Gene-Modified T Cells - Drug Profile 154
Plasmid DNA-MVA Prime Boost HIV-1 Vaccine - Drug Profile 155
APH-0812 - Drug Profile 156
Replication Defective HIV-1 Vaccine - Drug Profile 157
Clade B HIV Vaccine - Drug Profile 159
MazF-Based HIV-1 Gene Therapy - Drug Profile 161
AFO-18-CAF01 Vaccine - Drug Profile 163
TMB-657 - Drug Profile 164
VRC-01 - Drug Profile 165
DNA-HIV-PT123 + NYVAC-HIV-PT1 + NYVAC-HIV-PT4 - Drug Profile 167
HIV Vaccine - Drug Profile 169
Teravac HIV-1 Vaccine - Drug Profile 170
rAd5HVR48 HIV-1 Vaccine - Drug Profile 171
Retroviral Transduced T-Cell Therapy For HIV - Drug Profile 172
Anti-HIV Monoclonal Antibody - Drug Profile 173
L-644 - Drug Profile 174
HIV-1 Integrase Inhibitors - Drug Profile 175
DAC-HIV - Drug Profile 177
Leukothera - Drug Profile 178
Small Molecules to Inhibit CDK9 for HIV-1 Infection - Drug Profile 179
AT-96 - Drug Profile 180
GS-8374 - Drug Profile 181
HIV-1 Vaccine - Drug Profile 182
DS-003 - Drug Profile 183
M48-U1 - Drug Profile 184
Azuvirins - Drug Profile 186
Mutated tRNAs - Drug Profile 187
HIV Vaccine - Drug Profile 188
Cell Therapy for HIV-1 Infection - Drug Profile 189
Peptides Targeting TAR for HIV-1 Infection - Drug Profile 190
HIV-1 Integrase Inhibitor for Viral Infections - Drug Profile 192
HIV-1 Vaccine - Drug Profile 193
F2 - Drug Profile 194
SVC-2 - Drug Profile 195
SV6-B - Drug Profile 196
SV6-C - Drug Profile 197
SVH1-C - Drug Profile 198
Nuclear Export Inhibitors - Drug Profile 199
BMS-585248 - Drug Profile 200
VRC-03 Vaccine - Drug Profile 201
HIV-1 Mosaic Vaccine - Drug Profile 202
Tropolone Derivatives - Drug Profile 203
SIV Vaccine - Drug Profile 204
Cyclic V3 Peptide Vaccine - Drug Profile 205
Drug Targeting HIV-1 Reverse Transcriptase - Drug Profile 206
INS Peptide - Drug Profile 207
INRS Peptide - Drug Profile 208
Compounds Mimicking CD-4 Protein - Drug Profile 209
Maturation Inhibitor for HIV-1 - Drug Profile 210
CCL-14 - Drug Profile 211
givinostat - Drug Profile 212
HIV-1 Program - Drug Profile 214
aminoquinuride - Drug Profile 215
Drug For HIV-1 Infection - Drug Profile 216
PF-46396 - Drug Profile 217
PAV-8802 Series - Drug Profile 218
Small Molecules to Inhibit p25 and gp120 for HIV-1 Infection - Drug Profile 219
RC-100b - Drug Profile 220
Polyvalent HIV-1 Glycoprotein DNA Vaccines - Drug Profile 222
Drugs to Inhibit HIV-1 Protease for HIV-1 Infection - Drug Profile 223
RN-18 - Drug Profile 224
Ank(GAG)1D4 - Drug Profile 225
5-HN - Drug Profile 226
Drug Targeting Glycoprotein 41 - Drug Profile 227
Small Molecules to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection - Drug Profile 228
SVH1-D - Drug Profile 229
Compound-30 - Drug Profile 230
Compound-7 - Drug Profile 231
Drug For HIV-1 - Drug Profile 232
Small Molecule for HIV-1 Infection - Drug Profile 233
Nelfinavir Analogue - Drug Profile 234
Drugs Targeting HIV-1 Reverse Transcriptase for HIV-1 Infection - Drug Profile 235
Polypeptide For HIV-1 - Drug Profile 236
Drug For HIV-1 Infection - Drug Profile 237
GRL-0519 - Drug Profile 238
VRC-02 Vaccine - Drug Profile 239
Compound 11-b - Drug Profile 240
Drug to Inhibit Vif Protein for HIV-1 Infection - Drug Profile 241
Compound X - Drug Profile 242
Recombinant Peptides for HIV-1 Infection and STDs - Drug Profile 243
Drugs to Inhibit Reverse Transcriptase for Viral Infections - Drug Profile 244
AH-0109 - Drug Profile 245
HIV-1 Infection - Recent Pipeline Updates 246
HIV-1 Infection - Dormant Projects 267
HIV-1 Infection - Discontinued Products 274
HIV-1 Infection - Product Development Milestones 275
Featured News & Press Releases 275
Appendix 282
Methodology 282
Coverage 282
Secondary Research 282
Primary Research 282
Expert Panel Validation 282
Contact Us 283
Disclaimer 283
List of Tables
Number of Products under Development for HIV-1 Infection, H1 2014 20
Number of Products under Development for HIV-1 Infection - Comparative Analysis, H1 2014 21
Number of Products under Development by Companies, H1 2014 23
Number of Products under Development by Companies, H1 2014 (Contd..1) 24
Number of Products under Development by Companies, H1 2014 (Contd..2) 25
Number of Products under Investigation by Universities/Institutes, H1 2014 27
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 28
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 29
Comparative Analysis by Late Stage Development, H1 2014 30
Comparative Analysis by Clinical Stage Development, H1 2014 31
Comparative Analysis by Early Stage Development, H1 2014 32
Products under Development by Companies, H1 2014 33
Products under Development by Companies, H1 2014 (Contd..1) 34
Products under Development by Companies, H1 2014 (Contd..2) 35
Products under Development by Companies, H1 2014 (Contd..3) 36
Products under Investigation by Universities/Institutes, H1 2014 37
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 38
Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 39
Products under Investigation by Universities/Institutes, H1 2014 (Contd..3) 40
HIV-1 Infection - Pipeline by Bristol-Myers Squibb Company, H1 2014 41
HIV-1 Infection - Pipeline by Johnson & Johnson, H1 2014 42
HIV-1 Infection - Pipeline by Boehringer Ingelheim GmbH, H1 2014 43
HIV-1 Infection - Pipeline by GlaxoSmithKline plc, H1 2014 44
HIV-1 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2014 45
HIV-1 Infection - Pipeline by Gilead Sciences, Inc., H1 2014 46
HIV-1 Infection - Pipeline by Merck & Co., Inc., H1 2014 47
HIV-1 Infection - Pipeline by United Biomedical, Inc., H1 2014 48
HIV-1 Infection - Pipeline by Kaketsuken K.K., H1 2014 49
HIV-1 Infection - Pipeline by Aphios Corporation, H1 2014 50
HIV-1 Infection - Pipeline by Pfizer Inc., H1 2014 51
HIV-1 Infection - Pipeline by Koronis Pharma, Inc., H1 2014 52
HIV-1 Infection - Pipeline by Crucell N.V., H1 2014 53
HIV-1 Infection - Pipeline by GeoVax Labs, Inc., H1 2014 54
HIV-1 Infection - Pipeline by ConjuChem Biotechnologies Inc., H1 2014 56
HIV-1 Infection - Pipeline by Critical Outcome Technologies Inc., H1 2014 57
HIV-1 Infection - Pipeline by Takara Bio Inc., H1 2014 58
HIV-1 Infection - Pipeline by Bionor Pharma ASA, H1 2014 59
HIV-1 Infection - Pipeline by Quantum Pharmaceuticals, H1 2014 60
HIV-1 Infection - Pipeline by Italfarmaco S.p.A., H1 2014 61
HIV-1 Infection - Pipeline by Vironova AB, H1 2014 62
HIV-1 Infection - Pipeline by ViroStatics, srl, H1 2014 63
HIV-1 Infection - Pipeline by Argos Therapeutics, Inc., H1 2014 64
HIV-1 Infection - Pipeline by Myrexis, Inc., H1 2014 65
HIV-1 Infection - Pipeline by GeneCure LLC, H1 2014 66
HIV-1 Infection - Pipeline by Tobira Therapeutics, Inc., H1 2014 67
HIV-1 Infection - Pipeline by Pharis Biotec GmbH, H1 2014 68
HIV-1 Infection - Pipeline by Medestea Research & Production S.p.A., H1 2014 69
HIV-1 Infection - Pipeline by ViiV Healthcare Limited, H1 2014 70
HIV-1 Infection - Pipeline by RFS Pharma, LLC, H1 2014 71
HIV-1 Infection - Pipeline by Vichem Chemie Research Ltd., H1 2014 72
HIV-1 Infection - Pipeline by AltraVax Inc., H1 2014 73
HIV-1 Infection - Pipeline by TaiMed Biologics Inc., H1 2014 74
HIV-1 Infection - Pipeline by InnaVirVax SA, H1 2014 75
HIV-1 Infection - Pipeline by Valens Therapeutics, Inc., H1 2014 76
HIV-1 Infection - Pipeline by Susavion Biosciences, Inc., H1 2014 77
HIV-1 Infection - Pipeline by AbbVie Inc., H1 2014 78
Assessment by Monotherapy Products, H1 2014 79
Assessment by Combination Products, H1 2014 80
Number of Products by Stage and Target, H1 2014 83
Number of Products by Stage and Mechanism of Action, H1 2014 87
Number of Products by Stage and Route of Administration, H1 2014 90
Number of Products by Stage and Molecule Type, H1 2014 93
HIV-1 Infection Therapeutics - Recent Pipeline Updates, H1 2014 255
HIV-1 Infection - Dormant Projects, H1 2014 276
HIV-1 Infection - Dormant Projects (Contd..1), H1 2014 277
HIV-1 Infection - Dormant Projects (Contd..2), H1 2014 278
HIV-1 Infection - Dormant Projects (Contd..3), H1 2014 279
HIV-1 Infection - Dormant Projects (Contd..4), H1 2014 280
HIV-1 Infection - Dormant Projects (Contd..5), H1 2014 281
HIV-1 Infection - Dormant Projects (Contd..6), H1 2014 282
HIV-1 Infection - Discontinued Products, H1 2014 283
List of Figures
Number of Products under Development for HIV-1 Infection, H1 2014 20
Number of Products under Development for HIV-1 Infection - Comparative Analysis, H1 2014 21
Number of Products under Development by Companies, H1 2014 22
Number of Products under Investigation by Universities/Institutes, H1 2014 26
Comparative Analysis by Late Stage Development, H1 2014 30
Comparative Analysis by Clinical Stage Development, H1 2014 31
Comparative Analysis by Early Stage Products, H1 2014 32
Assessment by Monotherapy Products, H1 2014 79
Assessment by Combination Products, H1 2014 80
Number of Products by Top 10 Target, H1 2014 81
Number of Products by Stage and Top 10 Target, H1 2014 82
Number of Products by Top 10 Mechanism of Action, H1 2014 85
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 86
Number of Products by Top 10 Route of Administration, H1 2014 89
Number of Products by Stage and Top 10 Route of Administration, H1 2014 90
Number of Products by Top 10 Molecule Type, H1 2014 91
Number of Products by Stage and Top 10 Molecule Type, H1 2014 92
